<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To evaluate outcomes of ablative allogeneic hematopoietic cell transplantation (HCT) in older patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: We treated 52 patients from 1979 to 2002 with a median age of 62.8 years (range, 60.1 to 67.8 years) using ablative preparative regimens followed by allogeneic HCT from sibling donors </plain></SENT>
<SENT sid="2" pm="."><plain>Diagnoses included <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; n = 35), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>; n = 8), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; n = 6), and other (n = 3) </plain></SENT>
<SENT sid="3" pm="."><plain>Conditioning regimens included <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY) and <z:chebi fb="0" ids="28901">busulfan</z:chebi> (BU) (67%), total-body irradiation and CY (21%), BU-fludarabine (10%), and CY (2%) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Eighteen (35%) of 52 patients are alive at a median of 4.6 years (range, 0.8 to 9.1 years) after transplantation </plain></SENT>
<SENT sid="5" pm="."><plain>Median overall survival (OS) and progression-free survival were 300 and 218 days, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Three-year OS and relapse rates are estimated to be 34% and 24%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Nonrelapse mortality (NRM) rates at 100 days and 3 years are estimated to be 27% and 43%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Grade 3 to 4 <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) occurred in 20% of patients, and <z:hpo ids='HP_0011010'>chronic</z:hpo> extensive GVHD was described in 53% of patients </plain></SENT>
<SENT sid="9" pm="."><plain>Fourteen (40%) of 35 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> are alive at a median of 2.8 years (range, 0.8 to 8.2 years) </plain></SENT>
<SENT sid="10" pm="."><plain>Four of six patients with <z:mp ids='MP_0005481'>CML</z:mp> in <z:hpo ids='HP_0011010'>chronic</z:hpo> or accelerated phase are alive at a median of 6.9 years (range, 4.1 to 9.1 years) after transplantation </plain></SENT>
<SENT sid="11" pm="."><plain>None of the patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:mp ids='MP_0005481'>CML</z:mp> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e>, or other diagnoses have survived </plain></SENT>
<SENT sid="12" pm="."><plain>Patients who underwent transplantation after 1993 had improved survival </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: These data suggest that allogeneic HCT is feasible in selected patients &gt; or = 60 years of age, although novel methods to reduce NRM while maintaining efficacy are needed </plain></SENT>
</text></document>